UA73097C2 - Method for manufacturing orally applicable multiple unit controlled-release dosage form with controlled release of food effect-independent active substance - Google Patents
Method for manufacturing orally applicable multiple unit controlled-release dosage form with controlled release of food effect-independent active substance Download PDFInfo
- Publication number
- UA73097C2 UA73097C2 UA2001042576A UA2001042576A UA73097C2 UA 73097 C2 UA73097 C2 UA 73097C2 UA 2001042576 A UA2001042576 A UA 2001042576A UA 2001042576 A UA2001042576 A UA 2001042576A UA 73097 C2 UA73097 C2 UA 73097C2
- Authority
- UA
- Ukraine
- Prior art keywords
- active substance
- polymer
- obtaining
- dosage form
- differs
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims abstract description 39
- 239000002552 dosage form Substances 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims description 44
- 230000009246 food effect Effects 0.000 title abstract description 6
- 235000021471 food effect Nutrition 0.000 title abstract description 4
- 238000004519 manufacturing process Methods 0.000 title abstract description 3
- 238000013270 controlled release Methods 0.000 title abstract 3
- 229920000642 polymer Polymers 0.000 claims abstract description 28
- 239000002245 particle Substances 0.000 claims abstract description 16
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 17
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 17
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 17
- 230000002035 prolonged effect Effects 0.000 claims description 17
- 230000009471 action Effects 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 238000001125 extrusion Methods 0.000 claims description 13
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 10
- 229960001597 nifedipine Drugs 0.000 claims description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 8
- 238000005469 granulation Methods 0.000 claims description 8
- 230000003179 granulation Effects 0.000 claims description 8
- 238000000354 decomposition reaction Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 238000012876 topography Methods 0.000 claims 1
- 235000013305 food Nutrition 0.000 description 19
- 239000008185 minitablet Substances 0.000 description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 239000003826 tablet Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000000654 additive Substances 0.000 description 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 239000002966 varnish Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000000576 coating method Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 229940126601 medicinal product Drugs 0.000 description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 239000011805 ball Substances 0.000 description 4
- -1 for example Substances 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 229920003176 water-insoluble polymer Polymers 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- DZGUJOWBVDZNNF-UHFFFAOYSA-N azanium;2-methylprop-2-enoate Chemical compound [NH4+].CC(=C)C([O-])=O DZGUJOWBVDZNNF-UHFFFAOYSA-N 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19842753A DE19842753A1 (de) | 1998-09-18 | 1998-09-18 | Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung |
| PCT/EP1999/006882 WO2000016748A1 (de) | 1998-09-18 | 1999-09-17 | Agitationsunabhängige pharmazeutische multiple-unit-retardzubereitungen und verfahren zu ihrer herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA73097C2 true UA73097C2 (en) | 2005-06-15 |
Family
ID=7881376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2001042576A UA73097C2 (en) | 1998-09-18 | 1999-09-17 | Method for manufacturing orally applicable multiple unit controlled-release dosage form with controlled release of food effect-independent active substance |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6805881B1 (et) |
| EP (1) | EP1113787B1 (et) |
| JP (1) | JP2002526437A (et) |
| KR (1) | KR100660072B1 (et) |
| CN (1) | CN1178650C (et) |
| AT (1) | ATE260645T1 (et) |
| AU (2) | AU5861499A (et) |
| BG (1) | BG105325A (et) |
| BR (1) | BR9913839A (et) |
| CA (1) | CA2344372C (et) |
| DE (2) | DE19842753A1 (et) |
| DK (1) | DK1113787T3 (et) |
| EE (1) | EE04700B1 (et) |
| ES (1) | ES2215404T3 (et) |
| HK (1) | HK1040932B (et) |
| HR (1) | HRP20010198A2 (et) |
| HU (1) | HUP0103669A3 (et) |
| ID (1) | ID28735A (et) |
| IL (2) | IL141532A0 (et) |
| NO (1) | NO20011211D0 (et) |
| NZ (1) | NZ510563A (et) |
| PL (1) | PL195543B1 (et) |
| PT (1) | PT1113787E (et) |
| RU (1) | RU2235540C2 (et) |
| SK (1) | SK285099B6 (et) |
| TR (1) | TR200100756T2 (et) |
| UA (1) | UA73097C2 (et) |
| WO (2) | WO2000016747A1 (et) |
| ZA (1) | ZA200101485B (et) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| US20020044962A1 (en) * | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
| DE10129725A1 (de) * | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
| AR034813A1 (es) † | 2001-07-20 | 2004-03-17 | Novartis Ag | Composiciones farmaceuticas y uso de las mismas |
| DE10300111A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
| DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| NZ555693A (en) | 2004-12-27 | 2010-10-29 | Eisai R&D Man Co Ltd | Matrix type sustained-release preparation containing donepezil |
| US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
| EP1685841A1 (en) * | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention and treatment of thromboembolic disorders |
| DE102005012561B4 (de) | 2005-03-18 | 2008-06-19 | Christian Beer | Verfahren zum Betrieb eines Werkstück-Transfersystems |
| DE102005045518A1 (de) * | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung |
| EP1934208B1 (de) | 2005-10-04 | 2011-03-23 | Bayer Schering Pharma Aktiengesellschaft | Neue polymorphe form von 5-chlor-n-({ ( 5s )-2-0x0-3-[4-( 3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl} -methyl)-2-thiophencarboxamid |
| DE102005047558A1 (de) * | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen |
| DE102005047561A1 (de) * | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
| CN100448432C (zh) * | 2006-10-26 | 2009-01-07 | 徐竹青 | 高溶出度尼莫地平分散片的制备方法 |
| DE102006051625A1 (de) * | 2006-11-02 | 2008-05-08 | Bayer Materialscience Ag | Kombinationstherapie substituierter Oxazolidinone |
| US7952167B2 (en) * | 2007-04-27 | 2011-05-31 | Taiwan Semiconductor Manufacturing Company, Ltd. | Scribe line layout design |
| MY153852A (en) * | 2009-01-28 | 2015-03-31 | Novartis Ag | Galenic formulations of organic compounds |
| US20100247646A1 (en) * | 2009-03-26 | 2010-09-30 | Ranbaxy Laboratories Limited | Extended release tablets of nisoldipine |
| PL2554168T3 (pl) | 2010-03-29 | 2018-05-30 | Astellas Pharma Inc. | Kompozycja farmaceutyczna do kontrolowanego uwalniania |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5482525A (en) | 1977-12-13 | 1979-06-30 | Aisan Ind Co Ltd | Exhaust gas recirculation system |
| US4226849A (en) * | 1979-06-14 | 1980-10-07 | Forest Laboratories Inc. | Sustained release therapeutic compositions |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| US4449983A (en) | 1982-03-22 | 1984-05-22 | Alza Corporation | Simultaneous delivery of two drugs from unit delivery device |
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| GB8514665D0 (en) * | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
| DE3612211A1 (de) | 1986-04-11 | 1987-10-15 | Basf Ag | Kontinuierliches verfahren zum tablettieren |
| DE3612212A1 (de) | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
| DE3720757A1 (de) | 1987-06-24 | 1989-01-05 | Bayer Ag | Dhp-manteltablette |
| DE3830353A1 (de) | 1988-09-07 | 1990-03-15 | Basf Ag | Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen |
| JPH03145418A (ja) | 1989-10-27 | 1991-06-20 | Sumitomo Pharmaceut Co Ltd | 塩基性薬物塩酸塩の徐放性製剤 |
| EP0580860B2 (en) | 1991-04-16 | 2004-12-15 | Nippon Shinyaku Company, Limited | Method of manufacturing solid dispersion |
| DE4138513A1 (de) | 1991-11-23 | 1993-05-27 | Basf Ag | Feste pharmazeutische retardform |
| DE4413350A1 (de) | 1994-04-18 | 1995-10-19 | Basf Ag | Retard-Matrixpellets und Verfahren zu ihrer Herstellung |
| SE9402422D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New beads for controlled release and a pharmaceutical preparation containing the same |
| FR2725624B1 (fr) | 1994-10-14 | 1997-01-17 | Jouveinal Inst Rech | Procede de preparation de formes pharmaceutiques a liberation controlee |
| DE19504831A1 (de) | 1995-02-14 | 1996-09-05 | Basf Ag | Feste Wirkstoffzubereitungen enthaltend Hydroxypropylcellulose |
-
1998
- 1998-09-18 DE DE19842753A patent/DE19842753A1/de not_active Withdrawn
-
1999
- 1999-09-08 WO PCT/EP1999/006608 patent/WO2000016747A1/de active Application Filing
- 1999-09-08 AU AU58614/99A patent/AU5861499A/en not_active Abandoned
- 1999-09-17 HU HU0103669A patent/HUP0103669A3/hu unknown
- 1999-09-17 PL PL99346535A patent/PL195543B1/pl unknown
- 1999-09-17 BR BR9913839-5A patent/BR9913839A/pt not_active Application Discontinuation
- 1999-09-17 WO PCT/EP1999/006882 patent/WO2000016748A1/de active IP Right Grant
- 1999-09-17 ES ES99948770T patent/ES2215404T3/es not_active Expired - Lifetime
- 1999-09-17 UA UA2001042576A patent/UA73097C2/uk unknown
- 1999-09-17 CA CA002344372A patent/CA2344372C/en not_active Expired - Fee Related
- 1999-09-17 TR TR2001/00756T patent/TR200100756T2/xx unknown
- 1999-09-17 EE EEP200100161A patent/EE04700B1/et not_active IP Right Cessation
- 1999-09-17 JP JP2000573709A patent/JP2002526437A/ja not_active Ceased
- 1999-09-17 CN CNB998110299A patent/CN1178650C/zh not_active Expired - Fee Related
- 1999-09-17 NZ NZ510563A patent/NZ510563A/xx unknown
- 1999-09-17 AT AT99948770T patent/ATE260645T1/de not_active IP Right Cessation
- 1999-09-17 AU AU61918/99A patent/AU750617B2/en not_active Ceased
- 1999-09-17 KR KR1020017003495A patent/KR100660072B1/ko not_active IP Right Cessation
- 1999-09-17 IL IL14153299A patent/IL141532A0/xx not_active IP Right Cessation
- 1999-09-17 RU RU2001110355/15A patent/RU2235540C2/ru not_active IP Right Cessation
- 1999-09-17 EP EP99948770A patent/EP1113787B1/de not_active Expired - Lifetime
- 1999-09-17 PT PT99948770T patent/PT1113787E/pt unknown
- 1999-09-17 DK DK99948770T patent/DK1113787T3/da active
- 1999-09-17 SK SK372-2001A patent/SK285099B6/sk unknown
- 1999-09-17 US US09/787,229 patent/US6805881B1/en not_active Expired - Fee Related
- 1999-09-17 ID IDW20010651A patent/ID28735A/id unknown
- 1999-09-17 DE DE59908764T patent/DE59908764D1/de not_active Expired - Lifetime
-
2001
- 2001-02-20 IL IL141532A patent/IL141532A/en unknown
- 2001-02-22 ZA ZA200101485A patent/ZA200101485B/en unknown
- 2001-03-09 NO NO20011211A patent/NO20011211D0/no not_active Application Discontinuation
- 2001-03-09 BG BG105325A patent/BG105325A/bg unknown
- 2001-03-16 HR HR20010198A patent/HRP20010198A2/hr not_active Application Discontinuation
-
2002
- 2002-04-11 HK HK02102756.8A patent/HK1040932B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA73097C2 (en) | Method for manufacturing orally applicable multiple unit controlled-release dosage form with controlled release of food effect-independent active substance | |
| JP3350559B2 (ja) | 活性成分を含有する予め成形された微小粒子より製造される機械的に安定でかつ容易に分解し得る錠剤 | |
| JP4012689B2 (ja) | 新規徐放性経口製剤 | |
| US5283065A (en) | Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form | |
| US6294198B1 (en) | Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same | |
| JP2007509155A (ja) | クエチアピンを含有する薬剤 | |
| EP0523847A1 (en) | Taste mask coating for preparation of chewable pharmaceutical tablets | |
| AU2008309058B2 (en) | Galenical formulations of Aliskiren and Valsartan | |
| EP1491184A1 (en) | Soft tablet containing high molecular weight cellulosics | |
| CN102596252A (zh) | 用于对乙酰氨基酚的立即和延长释放的胃滞留药物组合物 | |
| MXPA04005667A (es) | Tableta farmaceutica de metformina de liberacion prolongada. | |
| EP1498114A1 (en) | Soft tablet containing high molecular weight cellulosics | |
| KR100661441B1 (ko) | 경구 제어 방출 제제 | |
| Nagaraju et al. | Design and evaluation of delayed and extended release tablets of mesalamine | |
| AU636538B2 (en) | Buffered matrix aspirin tablet | |
| RU2286766C2 (ru) | Новые композиции пролонгированного действия для перорального введения | |
| CZ2001984A3 (cs) | Retardované farmaceutické vícesložkové přípravky nezávislé na míchání a způsob jejich výroby | |
| MXPA01002821A (en) | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same | |
| Mal et al. | EXTENDED RELEASE TABLET |